标题
Advances in targeted therapy for acute myeloid leukemia
作者
关键词
-
出版物
Biomarker Research
Volume 8, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-20
DOI
10.1186/s40364-020-00196-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
- (2020) Jorge E. Cortes et al. BLOOD
- Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
- (2020) Justin M. Watts et al. BLOOD
- Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
- (2020) David Martínez-Cuadrón et al. CLINICAL DRUG INVESTIGATION
- Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
- (2020) Justin A. Caravella et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia
- (2020) Sandipkumar H. Patel et al. Journal of the National Comprehensive Cancer Network
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis
- (2020) Lixing Liu et al. Frontiers in Oncology
- Glasdegib: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
- (2019) Haijiao Zhang et al. Nature Communications
- Gilteritinib: First Global Approval
- (2019) Sohita Dhillon DRUGS
- FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
- (2019) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
- (2019) Eunice S. Wang BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Li Xuan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
- (2019) Masaru Katoh CLINICAL SCIENCE
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- FLT3 inhibitor quizartinib (AC220)
- (2019) Kiran Naqvi et al. LEUKEMIA & LYMPHOMA
- Quizartinib (AC220): a promising option for acute myeloid leukemia
- (2019) Fang Zhou et al. Drug Design Development and Therapy
- Prognostic Significance of Baseline FLT3 ‐ITD Mutant Allele Level in Acute Myeloid Leukemia Treated with Intensive Chemotherapy With/Without Sorafenib
- (2019) Fevzi Yalniz et al. AMERICAN JOURNAL OF HEMATOLOGY
- Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia
- (2019) Koji Sasaki et al. CANCER
- Hedgehog signaling inhibitors in solid and hematological cancers
- (2019) Jorge E. Cortes et al. CANCER TREATMENT REVIEWS
- Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Martin S. Tallman et al. Journal of the National Comprehensive Cancer Network
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation
- (2019) Keith W Pratz et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
- (2019) Daniel R Reed et al. Cancer Management and Research
- Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation
- (2019) Fang Chen et al. BONE MARROW TRANSPLANTATION
- Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3
- (2019) Chunxiao Zhang et al. CANCER
- Hematological malignancies and molecular targeting therapy
- (2019) Akira Shimada EUROPEAN JOURNAL OF PHARMACOLOGY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
- (2019) Eunice S. Wang BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
- (2019) Konstanze Döhner et al. BLOOD
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML
- (2018) Jorge E. Cortes et al. BLOOD
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
- (2018) Li Xuan et al. CANCER
- Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
- (2018) Michael R. Savona et al. CLINICAL CANCER RESEARCH
- Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population
- (2018) Hui Wei et al. Journal of Hematology & Oncology
- Precision therapy for acute myeloid leukemia
- (2018) Xue Yang et al. Journal of Hematology & Oncology
- Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia
- (2018) Martin Tallman Journal of the National Comprehensive Cancer Network
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enasidenib for the treatment of acute myeloid leukemia
- (2018) James Dugan et al. Expert Review of Clinical Pharmacology
- Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
- (2018) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
- (2018) Eytan M. Stein et al. BLOOD
- Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
- (2018) Richard F. Schlenk et al. BLOOD
- FLT3 inhibitors in acute myeloid leukemia
- (2018) Mei Wu et al. Journal of Hematology & Oncology
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
- (2017) Maria Larrosa-Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment
- (2016) Maximilian Fleischmann et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Isocitrate dehydrogenase mutations in myeloid malignancies
- (2016) B C Medeiros et al. LEUKEMIA
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
- (2015) Hamid Ali Nagi Al-Jamal et al. BMC CANCER
- A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
- (2015) Walter Fiedler et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
- (2015) Raoul Tibes et al. Journal of Hematology & Oncology
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment
- (2015) S V Singh et al. Cell Death & Disease
- Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex
- (2015) Naoshad Mohammad et al. Scientific Reports
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
- (2014) A P Im et al. LEUKEMIA
- Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
- (2013) Steven M. Chan et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
- (2013) J.-A. Losman et al. SCIENCE
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells
- (2012) Chieh-Lin Jerry Teng et al. ANNALS OF HEMATOLOGY
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers
- (2012) S M Sengsayadeth et al. BONE MARROW TRANSPLANTATION
- Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation
- (2012) Elisabeth Zirm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2010) Lenny Dang et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now